40-F Filing

AURINIA PHARMACEUTICALS INC. CIK: 1600620 FY 2019

Filing Information

Form Type	40-F
Accession Number	`0001628280-20-003036`
Period End Date	20191231
Filing Date	20200305
Fiscal Year	2019
Fiscal Period	FY
XBRL Instance	auph-20191231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 57 Income Statement 36 Cash Flow Statement 60 Stockholders Equity 16

Balance Sheet 57 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalents`	$165.63M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalents`	$117.97M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalents`	$306.02M	USD	Point-in-time
Short term investments (note 5)	`CurrentInvestments`	-	USD	Point-in-time
Short term investments (note 5)	`CurrentInvestments`	$7.83M	USD	Point-in-time
Short term investments (note 5)	`CurrentInvestments`	$7.89M	USD	Point-in-time
Accounts receivable and accrued interest receivable	`CurrentTradeReceivables`	$217.00K	USD	Point-in-time
Accounts receivable and accrued interest receivable	`CurrentTradeReceivables`	$368.00K	USD	Point-in-time
Prepaid expenses and deposits	`CurrentPrepaymentsAndOtherCurrentAssets`	$6.78M	USD	Point-in-time
Prepaid expenses and deposits	`CurrentPrepaymentsAndOtherCurrentAssets`	$8.75M	USD	Point-in-time
Current assets	`CurrentAssets`	$315.14M	USD	Point-in-time
Current assets	`CurrentAssets`	$132.85M	USD	Point-in-time
Clinical trial contract deposits	`LongtermDeposits`	$209.00K	USD	Point-in-time
Clinical trial contract deposits	`LongtermDeposits`	$358.00K	USD	Point-in-time
Property and equipment (note 6)	`PropertyPlantAndEquipment`	$31.00K	USD	Point-in-time
Property and equipment (note 6)	`PropertyPlantAndEquipment`	$93.00K	USD	Point-in-time
Property and equipment (note 6)	`PropertyPlantAndEquipment`	$41.00K	USD	Point-in-time
Acquired intellectual property and other intangible assets (note 7)	`IntangibleAssetsOtherThanGoodwill`	$12.62M	USD	Point-in-time
Acquired intellectual property and other intangible assets (note 7)	`IntangibleAssetsOtherThanGoodwill`	$14.12M	USD	Point-in-time
Acquired intellectual property and other intangible assets (note 7)	`IntangibleAssetsOtherThanGoodwill`	$11.24M	USD	Point-in-time
Assets	`Assets`	$145.86M	USD	Point-in-time
Assets	`Assets`	$326.68M	USD	Point-in-time
Accounts payable and accrued liabilities (note 8)	`TradeAndOtherCurrentPayables`	$11.18M	USD	Point-in-time
Accounts payable and accrued liabilities (note 8)	`TradeAndOtherCurrentPayables`	$7.07M	USD	Point-in-time
Deferred revenue (note 10)	`DeferredIncomeClassifiedAsCurrent`	$118.00K	USD	Point-in-time
Deferred revenue (note 10)	`DeferredIncomeClassifiedAsCurrent`	$118.00K	USD	Point-in-time
Contingent consideration (note 11)	`Currentcontingentconsideration`	$72.00K	USD	Point-in-time
Contingent consideration (note 11)	`Currentcontingentconsideration`	-	USD	Point-in-time
Current liabilities	`CurrentLiabilities`	$7.26M	USD	Point-in-time
Current liabilities	`CurrentLiabilities`	$11.29M	USD	Point-in-time
Deferred revenue (note 10)	`DeferredIncomeClassifiedAsNoncurrent`	$324.00K	USD	Point-in-time
Deferred revenue (note 10)	`DeferredIncomeClassifiedAsNoncurrent`	$206.00K	USD	Point-in-time
Contingent consideration (note 11)	`Noncurrentcontingentconsideration`	$5.11M	USD	Point-in-time
Contingent consideration (note 11)	`Noncurrentcontingentconsideration`	$3.96M	USD	Point-in-time
Royalty obligation (note 12)	`KeyManagementPersonnelCompensationObligationNoncurrent`	-	USD	Point-in-time
Royalty obligation (note 12)	`KeyManagementPersonnelCompensationObligationNoncurrent`	$7.20M	USD	Point-in-time
Derivative warrant liabilities (note 13)	`NoncurrentDerivativeFinancialLiabilities`	$21.75M	USD	Point-in-time
Derivative warrant liabilities (note 13)	`NoncurrentDerivativeFinancialLiabilities`	$29.35M	USD	Point-in-time
Liabilities	`Liabilities`	$33.29M	USD	Point-in-time
Liabilities	`Liabilities`	$53.17M	USD	Point-in-time
Shareholders Equity	`Warrants`	-	USD	Point-in-time
Shareholders Equity	`Warrants`	-	USD	Point-in-time
Common shares (note 14)	`IssuedCapital`	$504.65M	USD	Point-in-time
Common shares (note 14)	`IssuedCapital`	$790.47M	USD	Point-in-time
Contributed surplus	`CapitalReserve`	$23.66M	USD	Point-in-time
Contributed surplus	`CapitalReserve`	$24.69M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncome`	$-805.00K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncome`	$-805.00K	USD	Point-in-time
Deficit	`RetainedEarnings`	$-539.81M	USD	Point-in-time
Deficit	`RetainedEarnings`	$-415.96M	USD	Point-in-time
Equity	`Equity`	$112.58M	USD	Point-in-time
Equity	`Equity`	$165.82M	USD	Point-in-time
Equity	`Equity`	$273.52M	USD	Point-in-time
Equity and liabilities	`EquityAndLiabilities`	$326.68M	USD	Point-in-time
Equity and liabilities	`EquityAndLiabilities`	$145.86M	USD	Point-in-time
Commitments and contingencies (note 20)	`CommitmentsAndContingencies1`	-	USD	Point-in-time
Commitments and contingencies (note 20)	`CommitmentsAndContingencies1`	-	USD	Point-in-time

Income Statement 36 line items

Line Item	Tag	Value	Unit	Period
Licensing revenue	`LicenceFeeIncome`	$318.00K	USD	Annual
Licensing revenue	`LicenceFeeIncome`	$118.00K	USD	Annual
Contract revenue	`Researchanddevelopmentrevenue`	-	USD	Annual
Contract revenue	`Researchanddevelopmentrevenue`	$345.00K	USD	Annual
Revenue	`Revenue`	$463.00K	USD	Annual
Revenue	`Revenue`	$318.00K	USD	Annual
Research and development (note 15)	`ResearchAndDevelopmentExpense`	$41.38M	USD	Annual
Research and development (note 15)	`ResearchAndDevelopmentExpense`	$52.87M	USD	Annual
Corporate, administration and business development (note 15)	`GeneralAndAdministrativeExpense`	$13.67M	USD	Annual
Corporate, administration and business development (note 15)	`GeneralAndAdministrativeExpense`	$22.15M	USD	Annual
Amortization of acquired intellectual property and other intangible assets (note 7)	`AmortisationIntangibleAssetsOtherThanGoodwill`	$1.54M	USD	Annual
Amortization of acquired intellectual property and other intangible assets (note 7)	`AmortisationIntangibleAssetsOtherThanGoodwill`	$1.39M	USD	Annual
Amortization of property and equipment (note 6)	`DepreciationPropertyPlantAndEquipment`	$20.00K	USD	Annual
Amortization of property and equipment (note 6)	`DepreciationPropertyPlantAndEquipment`	$159.00K	USD	Annual
Other expenses (note 16)	`OtherOperatingIncomeExpense`	$-8.99M	USD	Annual
Other expenses (note 16)	`OtherOperatingIncomeExpense`	$-169.00K	USD	Annual
Expenses	`OperatingExpense`	$85.56M	USD	Annual
Expenses	`OperatingExpense`	$56.79M	USD	Annual
Loss before interest income, finance costs, change in estimated fair value of derivative warrant liabilities and income taxes	`ProfitLossFromOperatingActivities`	$-56.33M	USD	Annual
Loss before interest income, finance costs, change in estimated fair value of derivative warrant liabilities and income taxes	`ProfitLossFromOperatingActivities`	$-85.24M	USD	Annual
Interest income	`RevenueFromInterest`	$2.70M	USD	Annual
Interest income	`RevenueFromInterest`	$2.23M	USD	Annual
Finance costs (note 16)	`FinanceIncomeCost`	$-39.00K	USD	Annual
Finance costs (note 16)	`FinanceIncomeCost`	-	USD	Annual
Loss before change in estimated fair value of derivate warrant liabilities and income taxes	`ProfitLossFromOperatingActivitiesBeforeChangeinFairValueofDerivativesandTaxes`	$-82.58M	USD	Annual
Loss before change in estimated fair value of derivate warrant liabilities and income taxes	`ProfitLossFromOperatingActivitiesBeforeChangeinFairValueofDerivativesandTaxes`	$-54.09M	USD	Annual
Change in estimated fair value of derivative warrant liabilities (note 13)	`GainsLossesOnChangeInFairValueOfDerivatives`	$-9.95M	USD	Annual
Change in estimated fair value of derivative warrant liabilities (note 13)	`GainsLossesOnChangeInFairValueOfDerivatives`	$-41.12M	USD	Annual
Loss before income taxes	`ProfitLossBeforeTax`	$-64.05M	USD	Annual
Loss before income taxes	`ProfitLossBeforeTax`	$-123.70M	USD	Annual
Income tax expense (note 17)	`IncomeTaxExpenseContinuingOperations`	$73.00K	USD	Annual
Income tax expense (note 17)	`IncomeTaxExpenseContinuingOperations`	$144.00K	USD	Annual
Net loss and comprehensive loss for the year	`ProfitLoss`	$-123.85M	USD	Annual
Net loss and comprehensive loss for the year	`ProfitLoss`	$-64.12M	USD	Annual
Basic and diluted loss per common share (in dollars per share)	`BasicAndDilutedEarningsLossPerShare`	$-1.33	USD	Annual
Basic and diluted loss per common share (in dollars per share)	`BasicAndDilutedEarningsLossPerShare`	$-0.76	USD	Annual

Cash Flow Statement 60 line items

Line Item	Tag	Value	Unit	Period
Net loss for the year	`ProfitLoss`	$-123.85M	USD	Annual
Net loss for the year	`ProfitLoss`	$-64.12M	USD	Annual
Amortization of deferred revenue	`AdjustmentsForIncreaseDecreaseInDeferredIncome`	$-118.00K	USD	Annual
Amortization of deferred revenue	`AdjustmentsForIncreaseDecreaseInDeferredIncome`	$-118.00K	USD	Annual
Amortization of property and equipment	`AdjustmentsForDepreciationExpense`	$159.00K	USD	Annual
Amortization of property and equipment	`AdjustmentsForDepreciationExpense`	$20.00K	USD	Annual
Amortization of acquired intellectual property and other intangible assets	`Amortizationofacquiredintellectualpropertyandotherintangibleassets`	$1.39M	USD	Annual
Amortization of acquired intellectual property and other intangible assets	`Amortizationofacquiredintellectualpropertyandotherintangibleassets`	$1.54M	USD	Annual
Change in value and amortization of short term investments discount (note 20)	`AdjustmentsForFairValueGainsLosses`	$5.00K	USD	Annual
Change in value and amortization of short term investments discount (note 20)	`AdjustmentsForFairValueGainsLosses`	$13.00K	USD	Annual
Revaluation of contingent consideration	`Revaluationofcontingentconsiderations`	$1.19M	USD	Annual
Revaluation of contingent consideration	`Revaluationofcontingentconsiderations`	$236.00K	USD	Annual
Unrealized foreign exchange on lease liability	`UnrealizedForeignExchangeExpenseIncomeOnLeaseLiability`	-	USD	Annual
Unrealized foreign exchange on lease liability	`UnrealizedForeignExchangeExpenseIncomeOnLeaseLiability`	$18.00K	USD	Annual
Interest expense	`AdjustmentsForInterestExpense`	$39.00K	USD	Annual
Interest expense	`AdjustmentsForInterestExpense`	-	USD	Annual
Gain on derecognition of right-of-use asset	`GainOnDerecognitionOfRightofUseAsset`	-	USD	Annual
Gain on derecognition of right-of-use asset	`GainOnDerecognitionOfRightofUseAsset`	$54.00K	USD	Annual
Royalty obligation expense (note 12)	`Keymanagementpersonnelcompensationobligationexpense`	-	USD	Annual
Royalty obligation expense (note 12)	`Keymanagementpersonnelcompensationobligationexpense`	$7.20M	USD	Annual
Change in estimated fair value of derivative warrant liabilities	`AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives`	$-41.12M	USD	Annual
Change in estimated fair value of derivative warrant liabilities	`AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives`	$-9.95M	USD	Annual
Stock-based compensation	`AdjustmentsForSharebasedPayments`	$6.86M	USD	Annual
Stock-based compensation	`AdjustmentsForSharebasedPayments`	$7.41M	USD	Annual
Adjustments to reconcile profit (loss)	`AdjustmentsForReconcileProfitLoss`	$-45.61M	USD	Annual
Adjustments to reconcile profit (loss)	`AdjustmentsForReconcileProfitLoss`	$-65.48M	USD	Annual
Contingent consideration milestones paid	`Paymentofcontingentconsiderationmilestoneachievement`	-	USD	Annual
Contingent consideration milestones paid	`Paymentofcontingentconsiderationmilestoneachievement`	$100.00K	USD	Annual
Net change in other operating assets and liabilities (note 20)	`IncreaseDecreaseInWorkingCapital`	$6.00M	USD	Annual
Net change in other operating assets and liabilities (note 20)	`IncreaseDecreaseInWorkingCapital`	$-2.13M	USD	Annual
Net cash used in operating activities	`CashFlowsFromUsedInOperatingActivities`	$-63.46M	USD	Annual
Net cash used in operating activities	`CashFlowsFromUsedInOperatingActivities`	$-51.61M	USD	Annual
Proceeds on maturity of short term investments	`ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities`	$36.09M	USD	Annual
Proceeds on maturity of short term investments	`ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities`	$7.88M	USD	Annual
Purchase of short term investments	`PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities`	$36.08M	USD	Annual
Purchase of short term investments	`PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities`	-	USD	Annual
Purchase of equipment	`PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities`	$87.00K	USD	Annual
Purchase of equipment	`PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities`	$30.00K	USD	Annual
Capitalized patent costs	`PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities`	$45.00K	USD	Annual
Capitalized patent costs	`PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities`	$17.00K	USD	Annual
Net cash generated from (used in) investing activities	`CashFlowsFromUsedInInvestingActivities`	$7.78M	USD	Annual
Net cash generated from (used in) investing activities	`CashFlowsFromUsedInInvestingActivities`	$-66.00K	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromExerciseOfOptions`	$13.75M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromExerciseOfOptions`	$943.00K	USD	Annual
Proceeds from exercise of derivative warrants	`Proceedsfromexerciseofderivativewarrants`	$6.99M	USD	Annual
Proceeds from exercise of derivative warrants	`Proceedsfromexerciseofderivativewarrants`	-	USD	Annual
Principal elements of lease payments	`PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities`	$-127.00K	USD	Annual
Principal elements of lease payments	`PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromIssuingOtherEquityInstruments`	$3.07M	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromIssuingOtherEquityInstruments`	-	USD	Annual
Net cash generated from financing activities	`CashFlowsFromUsedInFinancingActivities`	$4.01M	USD	Annual
Net cash generated from financing activities	`CashFlowsFromUsedInFinancingActivities`	$243.73M	USD	Annual
Increase (decrease) in cash and cash equivalents during the year	`IncreaseDecreaseInCashAndCashEquivalents`	$188.05M	USD	Annual
Increase (decrease) in cash and cash equivalents during the year	`IncreaseDecreaseInCashAndCashEquivalents`	$-47.66M	USD	Annual
Cash and cash equivalents Beginning of year	`CashAndCashEquivalents`	$165.63M	USD	Point-in-time
Cash and cash equivalents Beginning of year	`CashAndCashEquivalents`	$117.97M	USD	Point-in-time
Cash and cash equivalents Beginning of year	`CashAndCashEquivalents`	$306.02M	USD	Point-in-time
Cash and cash equivalents End of year	`CashAndCashEquivalents`	$165.63M	USD	Point-in-time
Cash and cash equivalents End of year	`CashAndCashEquivalents`	$117.97M	USD	Point-in-time
Cash and cash equivalents End of year	`CashAndCashEquivalents`	$306.02M	USD	Point-in-time

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Equity, opening balance	`Equity`	$112.58M	USD	Point-in-time
Equity, opening balance	`Equity`	$165.82M	USD	Point-in-time
Equity, opening balance	`Equity`	$273.52M	USD	Point-in-time
Issue of common shares	`IssueOfEquity`	$236.75M	USD	Annual
Share issue costs	`ShareIssueRelatedCost`	$13.63M	USD	Annual
Exercise of derivative warrants	`IncreaseDecreaseThroughExerciseOfWarrantsEquity`	$3.07M	USD	Annual
Exercise of derivative warrants	`IncreaseDecreaseThroughExerciseOfWarrantsEquity`	$40.51M	USD	Annual
Exercise of stock options	`IncreaseDecreaseThroughExerciseOfOptions`	$13.75M	USD	Annual
Exercise of stock options	`IncreaseDecreaseThroughExerciseOfOptions`	$943.00K	USD	Annual
Stock-based compensation	`IncreaseDecreaseThroughSharebasedPaymentTransactions`	$6.86M	USD	Annual
Stock-based compensation	`IncreaseDecreaseThroughSharebasedPaymentTransactions`	$7.41M	USD	Annual
Net loss and comprehensive loss for the year	`ProfitLoss`	$-123.85M	USD	Annual
Net loss and comprehensive loss for the year	`ProfitLoss`	$-64.12M	USD	Annual
Equity, closing balance	`Equity`	$112.58M	USD	Point-in-time
Equity, closing balance	`Equity`	$165.82M	USD	Point-in-time
Equity, closing balance	`Equity`	$273.52M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.